Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saiba Biotech pandemic influenza VLP vaccine
- Development stage
- Preclinical
- Lead developer
- Saiba Biotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Saiba Biotech's pandemic influenza vaccine is a virus-like particle (VLP)-based vaccine candidate currently in preclinical development. The vaccine is designed to present influenza antigens, such as hemagglutinin, in a highly repetitive and organized multivalent format that mimics the structure of a virus to elicit a potent and broad immune response against pandemic influenza strains. This approach aims to provide a rapid and effective response to emerging influenza threats without the use of infectious viral material. The development of this vaccine involves a network of academic and research partners, including the University of Zurich, the University of Oxford, ETH Zurich, the University of Dundee, CHUV, the Jenner Institute, and A*STAR Singapore.
- Other names
- VLP Pandemic FluVLP-based pandemic influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Saiba Biotech pandemic influenza VLP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saiba Biotech pandemic influenza VLP vaccine.